What are the key takeaways for Gilead Sciences, Inc ($GILD)?

Gilead Sciences reported Q2 2026 revenue of $7,803 million, representing a 10.2% YoY increase, driven by strong performance in HIV therapies and oncology. GAAP net income dropped sharply to -$10,496 million (diluted EPS of -$8.45) due to substantial upfront R&D and acquisition-related charges recorded during the period. Operating cash flow remained robust at $3,573 million and free cash flow reached $3,433 million, demonstrating strong cash conversion despite GAAP accounting losses.

Gilead Sciences, Inc (GILD) AI Stock Analysis & Earnings

Please enable JavaScript to continue using this application.

Overview Charts AI Summary Financials Valuation

Based on June 30, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Gilead Sciences, Inc. ($GILD)

Gilead Sciences, Inc (GILD) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $7,803 million with diluted EPS of $-8.45 and net income of -$10,496 million. Operating margin was -133.2%, and free cash flow was $3,433 million for the period. The strong top-line expansion was primarily propelled by sustained demand for flagship HIV treatments such as Biktarvy, alongside continued traction in the oncology portfolio including Trodelvy and cell therapies. Operating income and GAAP net margins were heavily impacted by significant upfront collaboration and in-process research and development expenses during the quarter, reflecting active pipeline investments. Despite the GAAP net loss, operating cash flow remained exceptionally strong at $3,573 million, underlining the cash-generative nature of Gilead's commercialized portfolio. Management continued to execute capital allocation priorities, including share repurchases of $346 million while maintaining liquidity to support ongoing clinical trials and strategic collaborations.

Key Takeaways

1.Gilead Sciences reported Q2 2026 revenue of $7,803 million, representing a 10.2% YoY increase, driven by strong performance in HIV therapies and oncology.
2.GAAP net income dropped sharply to -$10,496 million (diluted EPS of -$8.45) due to substantial upfront R&D and acquisition-related charges recorded during the period.
3.Operating cash flow remained robust at $3,573 million and free cash flow reached $3,433 million, demonstrating strong cash conversion despite GAAP accounting losses.
4.Flagship HIV treatment Biktarvy continued to anchor top-line stability, maintaining high market share across key geographies.
5.The company executed $346 million in common stock repurchases during Q2 2026, continuing its capital return program while managing total debt of $26,246 million.
6.Oncology segment expansion continues to advance through clinical updates and regulatory submissions for Trodelvy and cell therapy assets.

What They Do

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company's primary therapeutic focus areas include viral diseases (such as HIV, viral hepatitis B and C, and COVID-19), oncology, and inflammatory diseases. Flagship commercial products include market-leading single-tablet regimens for HIV like Biktarvy and Genvoya, Veklury for COVID-19, and advanced oncology therapies acquired through strategic transactions, including Trodelvy for metastatic triple-negative breast cancer and Yescarta/Tecartus cell therapies. Gilead's customer base comprises institutional healthcare providers, hospitals, clinics, government healthcare agencies, and group purchasing organizations globally, with significant commercial reach across North America, Europe, and Asia. Operating on a large scale, the company generates over $30 billion in annual revenue, employs more than 14,000 personnel worldwide, and maintains state-of-the-art research and manufacturing facilities. Gilead's business model is unique due to its dominant market position in chronic virology, where long-term patient adherence to specialized regimens creates high barriers to entry and predictable cash flows that fund aggressive pipeline diversification into oncology.

How They Make Money

Gilead recognizes revenue primarily when control of products is transferred to customers, typically upon shipment or delivery to wholesale distributors, specialty pharmacies, and healthcare institutions. The revenue model is heavily weighted toward product sales of proprietary pharmaceutical formulations, categorized primarily into HIV, Liver Diseases (Hepatitis B and C), Oncology, and Other products (including Veklury). Revenue is predominantly commercial and recurring in nature due to the chronic, lifelong treatment requirements of patients living with HIV and viral hepatitis, resulting in high repeat purchase rates and strong patient retention. Key business metrics monitored by management include product sales growth, gross margins (consistently averaging near 80%), RPO, and operating cash flow generation. Revenue growth is primarily driven by unit volume expansion in core HIV franchises, price adjustments, successful label expansions, and the commercial scaling of newly acquired oncology products, offsetting generic erosion of older patent-expired compounds.

Competitive Position

Gilead competes against major global pharmaceutical and biotechnology enterprises, including AbbVie, GlaxoSmithKline (ViiV Healthcare), Pfizer, Merck, Johnson & Johnson, and Bristol Myers Squibb. The company's primary competitive advantages lie in its scientific leadership in antiviral drug discovery, established global commercial infrastructure, high switching costs associated with complex chronic treatment regimens, and substantial balance sheet capacity to fund large-scale clinical trials and acquisitions. Relative to sector peers, Gilead trades at competitive valuation multiples, supported by a strong FCF yield near 6.8%, although Q2 2026 GAAP operating margin was -133.2% because of the quarter's large upfront R&D charges. Financial trends indicate steady top-line growth (5.5% TTM) and resilient gross margins (~79.6%), though profitability metrics are periodically volatile due to upfront R&D charges and business combinations. Competitive pressures persist from generic challengers, emerging long-acting injectables from rivals like ViiV Healthcare, and intense competition in oncology immuno-therapies.

Business Strategy & Moat

Gilead's strategic logic centers on defending and expanding its leadership in virology while aggressively transforming into a diversified oncology and immunology powerhouse. The moat type is anchored in intangible assets (proprietary patent portfolios and clinical data), high switching costs for chronic patients, and scale advantages in drug distribution and manufacturing. This moat is stable to widening as long-term HIV regimens like Biktarvy maintain high retention rates and pipeline assets mature. Capital allocation is balanced between disciplined internal R&D investment (exceeding $1.3B to $1.7B quarterly), strategic bolt-on acquisitions to bolster the oncology pipeline, debt management, and direct shareholder returns via dividends and share buybacks. The flywheel operates through cash generated from established antiviral franchises funding high-risk, high-reward oncology clinical development, which in turn establishes new long-term revenue pillars to mitigate future patent expirations.

Industry Outlook

The biopharmaceutical industry operates within a favorable long-term macro environment driven by aging global populations, rising healthcare expenditures, and rapid technological advancements in genomics and cellular immunotherapy. Near-term tailwinds include accelerating post-pandemic clinical trial execution, increasing demand for specialized oncology treatments, and supportive regulatory pathways for breakthrough therapies. Conversely, headwinds include ongoing pricing pressures from government healthcare policy reforms (such as the Inflation Reduction Act in the U.S.), patent cliffs for blockbuster small-molecule drugs, and stringent regulatory scrutiny over drug safety and manufacturing standards. Gilead is strategically positioned to navigate these trends through its established market presence and pivot toward high-value oncology markets.

Growth Drivers

•Continued volume expansion and market share gains of flagship HIV single-tablet regimen Biktarvy.
•Commercial scaling and label expansions of oncology products, including Trodelvy across metastatic breast and urothelial cancers.
•Advancement of cell therapy portfolios (Yescarta and Tecartus) into broader patient populations and earlier lines of therapy.
•Development pipeline progression in long-acting HIV prevention and treatment options.
•Strategic partnerships and bolt-on acquisitions enhancing the clinical pipeline.

Recent Developments

•Gilead reported Q2 2026 financial results highlighting 10.2% YoY revenue growth to $7.80 billion, accompanied by substantial upfront R&D charges impacting GAAP net income.
•Continued execution of the share repurchase program, with $346 million of common stock repurchased in Q2 2026.
•Ongoing clinical trial updates presented at major medical congresses regarding oncology and virology pipeline candidates.
•Maintenance of robust liquidity with $3.18 billion in cash and strong quarterly operating cash flow of $3.57 billion.

Catalysts

•Upcoming Phase 3 clinical trial data readouts for key oncology pipeline assets expected over the next 6 to 12 months.
•Regulatory filings and potential approvals for new HIV long-acting treatment formulations and expanded oncology indications.
•Quarterly financial results announcements, providing visibility into operating margin recovery following recent upfront R&D charges.
•Ongoing commercial uptake metrics for Trodelvy and cell therapies in global markets.

Share Repurchase / Buyback Program

•Gilead repurchased $346 million of common stock during the second quarter of 2026 under its ongoing share repurchase authorization.
•The company maintains active capital return programs balancing dividend distributions and opportunistic share buybacks while managing total debt obligations of $26.25 billion.

RPO & Key Performance Indicators

•Quarterly revenue grew 10.2% YoY to $7.80 billion in Q2 2026, driven by solid demand across virology and oncology portfolios.
•Gross margin remained strong at 79.8% in Q2 2026, reflecting the high-value nature of proprietary pharmaceutical product sales.
•Free cash flow reached $3,433 million in Q2 2026, supported by robust operating cash flow of $3,573 million.

Strengths

•Strong top-line growth with Q2 2026 revenue increasing 10.2% YoY to $7.80 billion.
•Exceptional cash conversion capabilities, evidenced by $3,433 million in free cash flow and $3,573 million in operating cash flow during Q2 2026.
•Maintained high gross margins of 79.8%, reflecting strong pricing power and product mix in proprietary antiviral and oncology lines.
•Dominant market leadership in HIV therapies anchored by flagship products like Biktarvy.
•Prudent capital allocation balancing strategic R&D reinvestment, debt servicing, and share repurchases ($346 million in Q2 2026).

AI Benefits & Opportunities

•Utilization of artificial intelligence and machine learning in drug discovery pipelines to accelerate target identification and optimize clinical trial design.
•Internal operational efficiencies through automated data processing and analytical tools across research and clinical operations.

Risks & Concerns for Gilead Sciences, Inc. ($GILD)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

AI-generated research for Gilead Sciences, Inc. (GILD, filings period ending June 30, 2026). AI summaries, reports, and scoring can be inaccurate or incorrect; accuracy and correctness are not guaranteed. Informational only; not investment advice or personalized guidance.Enumerated risk factors in this view may be abbreviated for anonymous or guest sessions. Full risk sections are available with full access.

Summary generated on Oct 13, 2026.

Peers of Gilead Sciences, Inc. (GILD)

ABBVDeep Dive

Gilead Sciences, Inc (GILD) AI Stock Analysis & Earnings

Based on June 30, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.